PAHCのチャート
PAHCの企業情報
| symbol | PAHC |
|---|---|
| 会社名 | Phibro Animal Health Corp. （フィブロ・アニマル・ヘルス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 フィブロ・アニマル・ヘルス（Phibro Animal Health Corporation）は世界的な多様化した動物健康とミネラル栄養会社である。同社は動物健康、ミネラル栄養と性能製品3つの事業を含む。同社は抗菌剤、抗コクシジウム剤、ワクチン、栄養補助食品及びミネラル栄養製品などの動物用健康製品を含む多様な製品を提供する。同社はまた、パーソナルケア、自動車、工業化学および化学触媒産業で使用するための特定の原料を製造・販売する。同社の医薬品飼料添加物（MFAs）及びその他の事業は、濃縮飼料製品で構成され、動物飼料で管理される。MFAとその他の事業は、Stafac、Terramycin、Neo-TerramycinおよびMecadoxを含む抗菌剤、並びにNicarb、Aviax、Aviax Plus、Coxistacおよびamproliumを含む抗コクシジウム剤の製造・販売からなる。 フィブロ・アニマル・ヘルスは米国で動物用医薬品と栄養剤を製造、販売。「スタファック」、「エスカリン」、「Vマックス」などのブランド名で家畜用の抗生物質、抗コクシジウム剤、ワクチン、栄養剤、ミネラル剤、特殊原料を提供。大規模農場が多い米国、ブラジル、中国、ロシア、オ―ストラリア、カナダなどに販売のタ―ゲットに置く。 phibro animal health corporation is a leading global diversified animal health and mineral nutrition company. we are dedicated to helping meet the growing demand for animal protein. we concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. for over 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. we develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. phibro animal health corporation reported net sales of $764 million for the fiscal year ended june 30, 2017. our more than 1,400 employees are proud to manufacture and market our |
| 本社所在地 | Glenpointe Centre East 3rd Floor 300 Frank W. Burr Boulevard Suite 21 Teaneck NJ 07666-6712 USA |
| 代表者氏名 | Jack Clifford Bendheim ジャッククリフォードベンドハイム |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 201-329-7300 |
| 設立年月日 | － |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 1500人 |
| url | www.pahc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pahc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 125.82100 |
| 終値（lastsale） | 42.89 |
| 時価総額（marketcap） | 1732951921.52 |
| 時価総額 | 時価総額（百万ドル） 1782.927 |
| 売上高 | 売上高（百万ドル） 819.98200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 216.14 |
| 当期純利益 | 当期純利益（百万ドル） 67.57500 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Phibro Animal Health Corp revenues increased 7% to $820M. Net income before extraordinary items increased 5% to $67.6M. Revenues reflect Animal Health segment increase of 7% to $531.7M Mineral Nutrition segment increase of 8% to $234.9M Latin America and Canada segment increase of 25% to $120.9M Israel segment increase of 18% to $109.2M. Net income was partially offset by Selling. |
PAHCのテクニカル分析
PAHCのニュース
Over-The-Counter (OTC) Veterinary Drugs Market is Set to Cross US$ 19 Billion at a CAGR of 7.9% from Forecast Period 2023 to 2033 | Future Market Insights, Inc. 2023/05/15 13:15:00 Accesswire
NEWARK, DE / ACCESSWIRE / May 15, 2023 / The Over-The-Counter (OTC) Veterinary DrugsMarket is anticipated to expand its roots at a steady CAGR of 7.9% between 2023 and 2033. The market is projected to have a market share of US$ 19.01 Billion by 2033 while it is likely to be valued at US$ 8.8 Billion in 2023. Higher amount of people adopting dogs and cats as their pets, especially post-pandemic is increasing the component markets. More people treat their pets as their family members. Hence, the care for their nutrition, health, and diseases comes first for the. The legalization of OTC veterinary drugs that can be bought without the vet''s prescription is flourishing the market growth. Get a PDF Sample with Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9190 Increased veterinary businesses, animal welfare authorities, and government pet shelter homes are also garnering market growth. Furthermore, the different forms of dosage and increased awareness among people about animal health are projected to flourish the market success.
Phibro Animal Health Corporation 2023 Q3 - Results - Earnings Call Presentation 2023/05/12 18:10:29 Seeking Alpha
The following slide deck was published by Phibro Animal Health Corporation in conjunction with their 2023 Q3 earnings call.
Phibro Animal Health Corporation (PAHC) Q3 2023 Earnings Call Transcript 2023/05/06 21:28:02 Seeking Alpha
Phibro Animal Health Corporation (NASDAQ:NASDAQ:PAHC) Q3 2023 Earnings Conference Call May 4, 2023 9:00 AM ETCompany ParticipantsDamian Finio - Chief Financial OfficerJack Bendheim -…
Phibro Animal Non-GAAP EPS of $0.29 misses by $0.04, revenue of $245.7M misses by $0.99M 2023/05/03 20:48:06 Seeking Alpha
Phibro Animal press release (PAHC): Q3 Non-GAAP EPS of $0.29 misses by $0.04.Revenue of $245.7M (+2.5% Y/Y) misses by $0.99M.FISCAL YEAR 2023 FINANCIAL GUIDANCEThe Company…
Recap: Phibro Animal Health Q3 Earnings 2023/05/03 20:44:00 Benzinga
Phibro Animal Health (NASDAQ: PAHC ) reported its Q3 earnings results on Wednesday, May 3, 2023 at 04:30 PM. Here''s what investors need to know about the announcement. Earnings Phibro Animal Health missed estimated earnings by 12.12%, reporting an EPS of $0.29 versus … Full story available on Benzinga.com
Over-The-Counter (OTC) Veterinary Drugs Market is Set to Cross US$ 19 Billion at a CAGR of 7.9% from Forecast Period 2023 to 2033 | Future Market Insights, Inc. 2023/05/15 13:15:00 Accesswire
NEWARK, DE / ACCESSWIRE / May 15, 2023 / The Over-The-Counter (OTC) Veterinary DrugsMarket is anticipated to expand its roots at a steady CAGR of 7.9% between 2023 and 2033. The market is projected to have a market share of US$ 19.01 Billion by 2033 while it is likely to be valued at US$ 8.8 Billion in 2023. Higher amount of people adopting dogs and cats as their pets, especially post-pandemic is increasing the component markets. More people treat their pets as their family members. Hence, the care for their nutrition, health, and diseases comes first for the. The legalization of OTC veterinary drugs that can be bought without the vet''s prescription is flourishing the market growth. Get a PDF Sample with Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9190 Increased veterinary businesses, animal welfare authorities, and government pet shelter homes are also garnering market growth. Furthermore, the different forms of dosage and increased awareness among people about animal health are projected to flourish the market success.
Phibro Animal Health Corporation 2023 Q3 - Results - Earnings Call Presentation 2023/05/12 18:10:29 Seeking Alpha
The following slide deck was published by Phibro Animal Health Corporation in conjunction with their 2023 Q3 earnings call.
Phibro Animal Health Corporation (PAHC) Q3 2023 Earnings Call Transcript 2023/05/06 21:28:02 Seeking Alpha
Phibro Animal Health Corporation (NASDAQ:NASDAQ:PAHC) Q3 2023 Earnings Conference Call May 4, 2023 9:00 AM ETCompany ParticipantsDamian Finio - Chief Financial OfficerJack Bendheim -…
Phibro Animal Non-GAAP EPS of $0.29 misses by $0.04, revenue of $245.7M misses by $0.99M 2023/05/03 20:48:06 Seeking Alpha
Phibro Animal press release (PAHC): Q3 Non-GAAP EPS of $0.29 misses by $0.04.Revenue of $245.7M (+2.5% Y/Y) misses by $0.99M.FISCAL YEAR 2023 FINANCIAL GUIDANCEThe Company…
Recap: Phibro Animal Health Q3 Earnings 2023/05/03 20:44:00 Benzinga
Phibro Animal Health (NASDAQ: PAHC ) reported its Q3 earnings results on Wednesday, May 3, 2023 at 04:30 PM. Here''s what investors need to know about the announcement. Earnings Phibro Animal Health missed estimated earnings by 12.12%, reporting an EPS of $0.29 versus … Full story available on Benzinga.com
Phibro Animal Health Corporation (PAHC) Q3 2023 Earnings Call Transcript 2023/05/06 21:28:02 Seeking Alpha
Phibro Animal Health Corporation (NASDAQ:NASDAQ:PAHC) Q3 2023 Earnings Conference Call May 4, 2023 9:00 AM ETCompany ParticipantsDamian Finio - Chief Financial OfficerJack Bendheim -…
Phibro Animal Non-GAAP EPS of $0.29 misses by $0.04, revenue of $245.7M misses by $0.99M 2023/05/03 20:48:06 Seeking Alpha
Phibro Animal press release (PAHC): Q3 Non-GAAP EPS of $0.29 misses by $0.04.Revenue of $245.7M (+2.5% Y/Y) misses by $0.99M.FISCAL YEAR 2023 FINANCIAL GUIDANCEThe Company…
Recap: Phibro Animal Health Q3 Earnings 2023/05/03 20:44:00 Benzinga
Phibro Animal Health (NASDAQ: PAHC ) reported its Q3 earnings results on Wednesday, May 3, 2023 at 04:30 PM. Here''s what investors need to know about the announcement. Earnings Phibro Animal Health missed estimated earnings by 12.12%, reporting an EPS of $0.29 versus … Full story available on Benzinga.com
Phibro Animal Health Corporation to Participate in Bank of America Securities 2023 Health Care Conference. 2023/04/05 20:00:00 Wallstreet:Online
Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America Securities 2023 Health Care Conference. Chief Financial Officer Damian Finio will address financial analysts and investors on Tuesday, May 9, 2023, at 4:20 PM PDT. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com.